Selective inhibition of c-Jun N-terminal-kinase targeting the upregulation of NGAL and degradation of the ECM lead not only to the prevention of AAA development, but also to regression of established AAA in two murine models [101]. This evidence concerns the gene LCN2 and triple-A syndrome.